84.00
0.66%
0.55
After Hours:
84.00
Intra Cellular Therapies Inc stock is traded at $84.00, with a volume of 336.59K.
It is up +0.66% in the last 24 hours and down -1.97% over the past month.
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
See More
Previous Close:
$83.45
Open:
$83.86
24h Volume:
336.59K
Relative Volume:
0.63
Market Cap:
$8.91B
Revenue:
$612.78M
Net Income/Loss:
$-86.37M
P/E Ratio:
-52.17
EPS:
-1.61
Net Cash Flow:
$-62.91M
1W Performance:
-1.30%
1M Performance:
-1.97%
6M Performance:
+9.69%
1Y Performance:
+19.40%
Intra Cellular Therapies Inc Stock (ITCI) Company Profile
Name
Intra Cellular Therapies Inc
Sector
Phone
(646) 440-9333
Address
135 ROUTE 202/206, BEDMINSTER, NY
Compare ITCI with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
ITCI
Intra Cellular Therapies Inc
|
84.00 | 8.91B | 612.78M | -86.37M | -62.91M | -0.87 |
ZTS
Zoetis Inc
|
164.28 | 74.12B | 9.15B | 2.43B | 2.31B | 5.32 |
HLN
Haleon Plc Adr
|
9.72 | 43.95B | 14.26B | 1.55B | 0 | 0.3383 |
TAK
Takeda Pharmaceutical Co Adr
|
13.17 | 41.75B | 30.27B | 1.93B | 3.45B | 0.6044 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
22.21 | 25.17B | 16.77B | -959.00M | 1.37B | -0.85 |
VTRS
Viatris Inc
|
12.49 | 14.91B | 15.05B | -883.30M | 1.89B | -0.74 |
Intra Cellular Therapies Inc Stock (ITCI) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Sep-06-24 | Upgrade | Piper Sandler | Neutral → Overweight |
Jan-03-24 | Initiated | Robert W. Baird | Outperform |
Dec-11-23 | Initiated | TD Cowen | Outperform |
Apr-20-23 | Initiated | Morgan Stanley | Overweight |
Aug-22-22 | Downgrade | Goldman | Buy → Neutral |
Jul-07-22 | Initiated | Mizuho | Buy |
Jun-14-22 | Initiated | UBS | Buy |
Apr-22-22 | Initiated | Piper Sandler | Neutral |
Feb-16-22 | Initiated | Goldman | Buy |
Sep-23-21 | Initiated | Needham | Buy |
Dec-15-20 | Initiated | BofA Securities | Buy |
Dec-10-20 | Initiated | Goldman | Buy |
Feb-20-20 | Initiated | Evercore ISI | Outperform |
Jan-31-20 | Downgrade | JP Morgan | Overweight → Neutral |
Dec-24-19 | Reiterated | Canaccord Genuity | Buy |
Aug-12-19 | Initiated | Jefferies | Buy |
Feb-26-18 | Initiated | JP Morgan | Overweight |
Feb-08-18 | Initiated | RBC Capital Mkts | Outperform |
Dec-15-17 | Initiated | Canaccord Genuity | Buy |
Nov-08-17 | Upgrade | SunTrust | Hold → Buy |
Sep-07-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
Aug-30-17 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
Aug-24-17 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
Aug-23-17 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
May-02-17 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
May-02-17 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
May-01-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
Dec-16-16 | Initiated | Cantor Fitzgerald | Overweight |
Sep-29-16 | Reiterated | RBC Capital Mkts | Outperform |
Sep-29-16 | Downgrade | SunTrust | Buy → Neutral |
View All
Intra Cellular Therapies Inc Stock (ITCI) Latest News
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Acquired by Principal Financial Group Inc. - MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Intra-Cellular Therapies' SWOT analysis: CAPLYTA drives stock potential amid patent challenges - Investing.com India
Intra-Cellular Therapies' SWOT analysis: CAPLYTA drives stock potential amid patent challenges By Investing.com - Investing.com South Africa
Geode Capital Management LLC Increases Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
S&P 500 Futures Drop in Premarket Trading; Intra-Cellular Therapies, Avantor Lag - Barron's
Franklin Resources Inc. Purchases 155,655 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
(ITCI) Technical Pivots with Risk Controls - Stock Traders Daily
State Street Corp Has $136.02 Million Stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Y Intercept Hong Kong Ltd Trims Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies' SWOT analysis: Caplyta's success drives stock potential - Investing.com
Intra-Cellular Therapies Presents Data from the CAPLYTA Adjunctive MDD Phase 3 Program at the American College of Neuropsychopharmacology Annual Meeting - The Manila Times
Intra-Cellular Therapies Presents Data from the CAPLYTA - GlobeNewswire
Intra-Cellular Therapies Presents Data from the CAPLYTA Adjunctive MDD Phase 3 Program at the American College - EIN News
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Holdings Decreased by Wellington Management Group LLP - MarketBeat
Intra-Cellular Therapies: Parkinson's Disease Drug Expansion Could Be The Next Huge Move - Seeking Alpha
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Sold by Point72 Asset Management L.P. - MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Sold by BNP Paribas Financial Markets - MarketBeat
Insider Selling: Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) CEO Sells 51,000 Shares of Stock - MarketBeat
Intra-cellular Therapies CEO sells $8.72 million in stock By Investing.com - Investing.com UK
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 11,104 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
ITCI Submits sNDA to the FDA for Expanded Use of Caplyta in MDD - MSN
Study Estimates 5 Million People Could Benefit from Magic Mushrooms for Depression Treatment - Managed Healthcare Executive
(ITCI) Investment Analysis and Advice - Stock Traders Daily
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Bought by Parkman Healthcare Partners LLC - MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Sold by Bank of Montreal Can - MarketBeat
Loss-Making Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Expected To Breakeven In The Medium-Term - Simply Wall St
HighVista Strategies LLC Has $548,000 Stock Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Erste Asset Management GmbH Purchases Shares of 23,400 Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies Seeks FDA Approval for Caplyta as Additional Treatment for Depression - Managed Healthcare Executive
Intra-Cellular Eyes Depression Approval for Caplyta as Stock Flies Under the Radar - BioSpace
Intra-Cellular Ther (ITCI-Q) QuotePress Release - The Globe and Mail
Point72 Hong Kong Ltd Sells 38,075 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies Submits Supplemental New Drug Application (sNDA) to FDA for CAPLYTA® (lumateperone) for the Treatment of Major Depressive Disorder as Adjunctive Therapy - The Manila Times
Intra-Cellular Therapies Submits Supplemental New Drug - GlobeNewswire
Intra-Cellular Therapies Says FDA Approved Caplyta to Treat Bipolar Depression, Shares up - Marketscreener.com
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Acquired by Bellevue Group AG - MarketBeat
Point72 Europe London LLP Lowers Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
54,629 Shares in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Purchased by Edgestream Partners L.P. - MarketBeat
Cerity Partners LLC Has $3.23 Million Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies stock rated Outperform by Mizuho, with 13% stock rise post-earnings - Investing.com UK
Why Is Intra-Cellular (ITCI) Up 2.2% Since Last Earnings Report? - Yahoo Finance
Vestal Point Capital LP Makes New Investment in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Suvretta Capital Management LLC Has $105.29 Million Stock Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Stake Decreased by Charles Schwab Investment Management Inc. - MarketBeat
Fmr LLC Sells 116,146 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
How Intra-Cellular surprised Wall Street by breaking character - BioPharma Dive
Cynosure Group LLC Purchases 8,909 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Makes New Investment in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Algert Global LLC Reduces Stock Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Natixis Advisors LLC Has $1.80 Million Stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra Cellular Therapies Inc Stock (ITCI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):